Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Edwards Lifesciences, LLC

Approvalsdevice change approved (PMA)27 Oct 2026

Edwards Lifesciences, LLC

27 Oct 2026: Device change approved (PMA) · SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent. Recorded in the openFDA device PMA data.

View the source record

Decided
27 Oct 2026
Device
SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent
Specialty
Cardiovascular
Type
Supplement (Normal 180 Day Track)
Reason
Change Design/Components/Specifications/Material
Reference
P200015 S077
Location
Irvine, CA
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Edwards Lifesciences, LLC

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Edwards Lifesciences, LLC in our registers.

More in Cardiovascular

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.